• español
    • English
  • Login
  • español 
    • español
    • English

UniversidaddeCádiz

Área de Biblioteca, Archivo y Publicaciones
Comunidades y colecciones
Ver ítem 
  •   RODIN Principal
  • Producción Científica
  • Artículos Científicos
  • Ver ítem
  •   RODIN Principal
  • Producción Científica
  • Artículos Científicos
  • Ver ítem
JavaScript is disabled for your browser. Some features of this site may not work without it.

Empagliflozin reduces vascular damage and cognitive impairment in a mixed murine model of Alzheimer's disease and type 2 diabetes

Thumbnail
Identificadores

URI: http://hdl.handle.net/10498/22860

DOI: 10.1186/s13195-020-00607-4

ISSN: 1758-9193

Ficheros
2020_168.pdf (2.246Mb)
Estadísticas
Ver estadísticas
Métricas y Citas
 
Compartir
Exportar a
Exportar a MendeleyRefworksEndNoteBibTexRIS
Metadatos
Mostrar el registro completo del ítem
Autor/es
Hierro Bujalance, Carmen; Infante-Garcia, Carmen; Marco Delgado, Ángel José delAutoridad UCA; Herrera, Marta; Carranza Naval, María JoséAutoridad UCA; Suarez, Javier; Alves Martinez, Pilar; Lubián López, Simón PedroAutoridad UCA; García Alloza, MónicaAutoridad UCA
Fecha
2020-04
Departamento/s
Biomedicina, Biotecnología y Salud Pública; Materno-Infantil y Radiología
Fuente
Alzheimer's Research & Therapy (2020) 12:40
Resumen
Background Both Alzheimer's disease (AD) and type 2 diabetes (T2D) share common pathological features including inflammation, insulin signaling alterations, or vascular damage. AD has no successful treatment, and the close relationship between both diseases supports the study of antidiabetic drugs to limit or slow down brain pathology in AD. Empagliflozin (EMP) is a sodium-glucose co-transporter 2 inhibitor, the newest class of antidiabetic agents. EMP controls hyperglycemia and reduces cardiovascular comorbidities and deaths associated to T2D. Therefore, we have analyzed the role of EMP at the central level in a complex mouse model of AD-T2D. Methods We have treated AD-T2D mice (APP/PS1xdb/db mice) with EMP 10 mg/kg for 22 weeks. Glucose, insulin, and body weight were monthly assessed. We analyzed learning and memory in the Morris water maze and the new object discrimination test. Postmortem brain assessment was conducted to measure brain atrophy, senile plaques, and amyloid-beta levels. Tau phosphorylation, hemorrhage burden, and microglia were also measured in the brain after EMP treatment. Results EMP treatment helped to maintain insulin levels in diabetic mice. At the central level, EMP limited cortical thinning and reduced neuronal loss in treated mice. Hemorrhage and microglia burdens were also reduced in EMP-treated mice. Senile plaque burden was lower, and these effects were accompanied by an amelioration of cognitive deficits in APP/PS1xdb/db mice. Conclusions Altogether, our data support a feasible role for EMP to reduce brain complications associated to AD and T2D, including classical pathological features and vascular disease, and supporting further assessment of EMP at the central level.
Materias
Alzheimer’s disease; Type 2 diabetes; Amyloid-β; Hemorrhage; Microglia; Tau; Cognition; Empagliflozin
Colecciones
  • Artículos Científicos [12009]
  • Articulos Científicos Biomedicina [582]
  • Artículos Científicos INIBICA [1093]
  • Articulos Científicos Mat. Inf. Rad. [137]
Atribución 4.0 Internacional
Esta obra está bajo una Licencia Creative Commons Atribución 4.0 Internacional

Listar

Todo RODINComunidades y ColeccionesPor fecha de publicaciónAutoresTítulosMateriasEsta colecciónPor fecha de publicaciónAutoresTítulosMaterias

Mi cuenta

AccederRegistro

Estadísticas

Ver Estadísticas de uso

Información adicional

Acerca de...Deposita en RODINPolíticasNormativasDerechos de autorEnlaces de interésEstadísticasNovedadesPreguntas frecuentes

RODIN está accesible a través de

OpenAIREOAIsterRecolectaHispanaEuropeanaBaseDARTOATDGoogle Académico

Enlaces de interés

Sherpa/RomeoDulcineaROAROpenDOARCreative CommonsORCID

RODIN está gestionado por el Área de Biblioteca, Archivo y Publicaciones de la Universidad de Cádiz

ContactoSugerenciasAtención al Usuario